Geron Co. (NASDAQ:GERN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Geron Co. (NASDAQ:GERN) has been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $5.68.

A number of analysts recently issued reports on GERN shares. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a report on Wednesday, February 26th. Scotiabank dropped their price objective on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. Needham & Company LLC dropped their price objective on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. B. Riley cut Geron from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Stifel Nicolaus dropped their price objective on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, February 27th.

Geron Stock Down 0.6 %

Shares of NASDAQ:GERN opened at $1.60 on Wednesday. The company has a market capitalization of $1.02 billion, a PE ratio of -5.00 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business has a fifty day moving average price of $2.73 and a two-hundred day moving average price of $3.65. Geron has a 1 year low of $1.46 and a 1 year high of $5.34.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million. Analysts forecast that Geron will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On Geron

Large investors have recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in shares of Geron during the 4th quarter valued at about $28,000. Integrated Wealth Concepts LLC purchased a new position in shares of Geron during the 4th quarter valued at about $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron during the 4th quarter valued at about $45,000. Readystate Asset Management LP purchased a new position in shares of Geron during the 3rd quarter valued at about $58,000. Finally, Empowered Funds LLC purchased a new position in shares of Geron during the 3rd quarter valued at about $67,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.